Annual report [Section 13 and 15(d), not S-K Item 405]

Discontinued Operations - Schedule of Reconciliation of Discontinued Operations (Details)

v3.25.1
Discontinued Operations - Schedule of Reconciliation of Discontinued Operations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Loss from discontinued operations, net of tax $ (3,839) $ (402)
Pharmaloz | Discontinued Operations, Disposed of by Sale    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenues, net 6,442 9,400
Cost of revenues 7,364 8,717
Gross (loss) profit (922) 683
Operating expenses:    
General and administration 2,569 1,060
Research and development 0 16
Total operating expenses 2,569 1,076
Loss from operations (3,491) (393)
Interest expense (378) (9)
Other income 30 0
Loss from discontinued operations, net of tax $ (3,839) $ (402)